[Use of cabergoline in persisting Cushing's disease].
Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors. It has also been reported effective for patients with hypercortisolism uncontrolled by conventional therapies. We describe the use of cabergoline in three patients with Cushing's disease, one of them presenting a silent ACTH-secreting pituitary tumor. Those patients underwent surgery and only one has been treated with radiation therapy. However persisting hypercortisolism motivated the use of cabergoline. We describe a decrease or a normalization in hypercortisolism; for one of the subjects, tumor growth seemed to be stopped. While cabergoline can induce a suppression of cortisol secretion or a corticotroph tumor shrinkage, the sites of action remain unclear.
Illouz
F
F
Service d'Endocrinologie, CHU Hôtel Dieu, 4 rue Larrey, 49033 Angers cedex 01. frillouz@chu-angers.fr
Dubois-Ginouves
S
S
Laboureau
S
S
Rohmer
V
V
Rodien
P
P
D000308:Adrenocortical Hyperfunction / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000652:urine; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000175:diagnosis* / Q000601:surgery
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline; D006854:Hydrocortisone